Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by Meritage Portfolio Management

Meritage Portfolio Management lifted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 20,755 shares of the specialty pharmaceutical company’s stock after acquiring an additional 979 shares during the quarter. Meritage Portfolio Management owned 0.06% of Collegium Pharmaceutical worth $595,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Emerald Advisers LLC raised its holdings in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after buying an additional 177,129 shares during the period. Geode Capital Management LLC lifted its stake in Collegium Pharmaceutical by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock worth $29,974,000 after acquiring an additional 5,464 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after acquiring an additional 116,327 shares during the period. Finally, Victory Capital Management Inc. grew its position in Collegium Pharmaceutical by 43.6% in the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after acquiring an additional 215,874 shares in the last quarter.

Collegium Pharmaceutical Stock Down 0.7 %

Shares of Collegium Pharmaceutical stock opened at $30.71 on Thursday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52-week low of $28.39 and a 52-week high of $42.29. The company has a market capitalization of $990.40 million, a P/E ratio of 13.24 and a beta of 0.82. The company has a 50 day moving average of $31.03 and a 200 day moving average of $34.14.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.